House of Lords Report Demands Urgent Action for UK’s Biotech Sector

Biotech, which leverages and adapts natural systems to address challenges in areas like healthcare, food security, and sustainable energy, is poised to drive innovation and economic growth worldwide. However, the report reveals systemic weaknesses that could undermine the UK’s ability to compete globally.

Baroness Brown of Cambridge, chair of the committee, underscored the urgency of the situation:

“Britain is a world-leader in scientific innovation, with a heritage that is the envy of the world. But all too frequently we are crashing into walls rather than smashing through ceilings.”

The Challenges Facing UK Biotech

The committee’s eight-month inquiry highlighted seven critical areas requiring immediate action: strategy, skills, regulation, infrastructure, investment, adoption, and governance. Of particular concern is the so-called “valley of death,” where UK biotech companies often falter due to a lack of investment needed to scale operations and compete on the global stage.

Baroness Brown elaborated:

“Pioneering companies urgently need to scale-up to become globally competitive – not get stuck in the investment ‘valley of death’... All too often we hear that when companies reach a certain size, they move abroad for better investment and development prospects, taking most of the economic benefit with them.”

The report warns that this trend threatens not only economic benefits but also the UK’s ability to lead in solving critical global challenges through biotech innovation.

A Growing Sector, But Job Opportunities at Risk

One of the most significant advantages of a thriving biotech sector is its potential to create high-quality, future-focused jobs. From research scientists and lab technicians to bioinformaticians and biotech entrepreneurs, the sector employs a diverse range of professionals.

Currently, the UK biotech sector supports thousands of jobs across research, manufacturing, and product development. However, the lack of investment and infrastructure to scale up companies in the UK risks these jobs migrating abroad along with the businesses.

Baroness Brown’s comments about companies relocating to other countries highlight this issue:

“All too often we hear that when companies reach a certain size, they move abroad for better investment and development prospects, taking most of the economic benefit with them.”

This not only leads to a loss of intellectual property and revenue but also drains the UK of talent and opportunities for growth. Without action, the UK risks missing out on the creation of a robust job market in biotech, which could otherwise drive local economies and support global innovation.

To ensure the UK remains competitive, the report suggests strengthening the education pipeline for biotech careers and providing more incentives for companies to retain their operations domestically. By addressing these gaps, the UK can secure both the economic and employment benefits of a thriving biotech sector.

Government Response

The Government has acknowledged the report’s findings and expressed its commitment to supporting the biotech sector. A spokesperson stated:

“Biotech is a technology with enormous potential, and we agree that it is critical to support home-grown biotech companies – which our bold national vision for biotech also makes the case for.”

The Government cited initiatives such as a £100 million investment in Biotech Mission Hubs and Awards and regulatory improvements through the new Regulatory Innovation Office. While these steps are encouraging, the committee argues that a more coordinated and aggressive approach is essential to secure the sector's future.

Why Biotech Matters

Biotech isn’t just another area of science; it is a transformative field capable of reshaping industries and addressing global issues like climate change, food insecurity, and disease. Falling behind in biotech would not only impact the UK’s economy but also its ability to influence the direction of future technologies.

The sector’s ability to create high-skill jobs further underscores its importance. A well-supported biotech industry can act as a magnet for talent, encourage innovation, and drive long-term economic growth.

What’s Next?

The House of Lords report is a call to action. It highlights the UK’s strengths but stresses the importance of overcoming barriers that hinder growth and investment in the biotech sector. With a concerted effort, the UK can maintain its leadership in this vital area of innovation.

Baroness Brown’s closing remarks emphasise the urgency:

“This failure to scale in the UK is a long-standing issue which requires an urgent, concerted, cross-government approach to fix.”

By addressing these challenges, the UK not only secures its position as a biotech leader but also ensures the creation of meaningful job opportunities that can benefit generations to come. The stakes are high, but the rewards of maintaining a strong and innovative biotech sector are even higher.

Source:

Don’t squander the scientific opportunity of a lifetime: UK must turbocharge its innovation to harness engineering biology, says Lords report - UK Parliament